Awakn’s Phase 3 Trial On Ketamine Therapy Gets Almost $2M From UK State Funding
[ad_1] Biotech psychedelics company Awakn Life Sciences Corp. AWKNF has been granted funding for 66% of the costs from its phase 3 clinical trial on ketamine therapy for alcohol use disorder…